French Validation of the Memorial Anxiety Scale for Patients With Prostate Cancer.
Memorial Anxiety Scale for Patients With Prostate Cancer: French Validation, Links With Quality Of Life and Future Temporal Perspective.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The psychological difficulties encountered by patients with prostate cancer are widely known. There are, however, problems in the identification of certain disorders that require appropriate psychological management. In order to diagnose patients with anxiety more finely, a prostate cancer-specific anxiety measurement scale (MAX-PC) was developed and validated. This scale includes three sub-dimensions: anxiety related to prostate cancer, anxiety related to the PSA assessment and fear of recurrence. This scale generally has good psychometric properties which are found in different populations and in different countries. The dimensions of the MAX-PC correlate with other anxiety measurement scales such as Beck or HADS, but do not show redundancy: it captures a specific anxiety related to the experience of patients with prostate cancer.
To date, this sclae is not validated in French, and its use in the frame of clinical trials or in routine practice require a first validation.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Marseille, France, 13298
- Institut Paoli Calmettes
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients with prostate cancer diagnosed within 12 months
Exclusion Criteria:
N/A
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Patients with prostate cancer
online questionnaire of MAX-PC
|
Scale measuring of the anxiety specific of prostate cancer, French version.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Total anxiety score assessed by the Memorial Anxiety Scale for Prostate Cancer (MAX-PC scale)
Time Frame: At inclusion
|
The scale is divided in 3 subscales: Prostate cancer Anxiety ; PSA anxiety and Fear of Recurrence.
The total score of the scale ranges from 0 to 54, with 54 indicating maximum anxiety.
Scores of the Prostate anxiety scale range from 0 to 33 ; with 33 indicating maximum anxiety.
Scores of the PSA anxiety scale range from 0 to 9 ; with 9 indicating maximum anxiety.
Score of the Fear of Recurrence scale range from 0 to 12; with 12 indicating maximum anxiety.
The total score is the sum of the 3 subscales scores.
|
At inclusion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Quality of Life (QoL) scores assessed by the SF-12 scale
Time Frame: At inclusion
|
12-item Short Form Health Survey (SF12), is a multipurpose generic measure oh health status. The SF-12 is weighted and summed to provide easily interpretable scales for physical and mental health. Physical and Mental Health Composite Scores (PCS & MCS) are computed using the scores of twelve questions and range from 0 to 100 where a zero score indicates the lowest level of health measured by the scales and 100 indicates the highest level of health. Higher values represent a better outcome. |
At inclusion
|
|
Anxiety score assessed by the HADS scale
Time Frame: At inclusion
|
The scores for anxiety can range from 0 to 21, depending on the presence and severity of the symptom.
Patients with a score higher than 7 are detected as having at least mild anxiety.
|
At inclusion
|
|
Depression score assessed by the HADS scale
Time Frame: At inclusion
|
The scores for depression can range from 0 to 21, depending on the presence and severity of the symptom.
Patients with a score higher than 7 are detected as having at least mild depression.
|
At inclusion
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MAC-PROSTATE-IPC 2016-009
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.